about
Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis25 Years of Proton Pump Inhibitors: A Comprehensive Review.Review article: the pharmacokinetics of rabeprazole in health and disease.Review article: drug interactions with agents used to treat acid-related diseases.Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.Review article: rabeprazole's tolerability profile in clinical trials.The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.The chiral bioconversion and preclinical pharmacokinetic analysis of (R)-(+)-rabeprazole in beagle dogs by HPLC and HPLC-MS/MS.One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypesDifferent effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.Gastroprotective Potential of Dalbergia sissoo Roxb. Stem Bark against Diclofenac-Induced Gastric Damage in RatsDementia, cognitive impairment and proton pump inhibitor therapy: A systematic review.Proton Pump Inhibitors: More Indigestion than Relief?A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.Therapeutic effect of Streptococcus thermophilus CRL 1190-fermented milk on chronic gastritis.A biochemical study on the gastroprotective effect of hydroalcoholic extract of Andrographis paniculata in rats.Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.Not a usual suspect; rabeprazole therapy presenting as a severe neuropsychiatric illness: case report.Determination of rabeprazole enantiomers in commercial tablets using immobilized cellulose-based stationary phase.Determination of rabeprazole enantiomers in dog plasma by supercritical fluid chromatography tandem mass spectrometry and its application to a pharmacokinetic study.Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure.Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
P2860
Q24289016-A2383B98-3BFB-49F2-A396-DF496B6C2D12Q28070003-8613DE2D-FE86-4C11-BAE2-6EDAC3E0060DQ33734843-53229D0E-BDCD-4EDE-9FAE-BDF9A444E4BBQ33734848-3D7E8A90-912A-48A9-9011-55142B9122BFQ33734852-994AA5F7-7098-455D-89FB-C2990D2CBE13Q33771063-DFC7F73D-D46A-4DAD-918D-76D68CF18AB0Q33866339-0B88E5E3-4672-4BF5-95C6-E2E46C675480Q33912651-F49BBB25-4CBE-4E02-AB84-07551F744F9BQ34736757-91549A59-0BB2-492D-8C08-C9960505F03DQ35011405-E1AF95A9-3F38-4E3E-8B62-21A65675F97CQ35827444-64FA7F4E-05B6-4B76-93D5-02767D34F185Q35827487-BD77670D-E990-4E4E-9699-E5A16632DAE6Q37353302-D4C2361A-3022-4DEA-9E9E-20D4F8262EAAQ38995773-3FBCD7F7-4EC6-432A-A1A3-768D09E77598Q39152043-C3346CBC-6305-4EC1-A517-B8E45D4ABAAFQ39409878-68C3F079-DD2E-4D53-BB40-56E3DD2FC91AQ39409884-60912CE4-9165-48A8-A407-1CFAE2127C8AQ39422116-511EF4A2-8AF6-468D-804D-E67E95CF468AQ39870352-69F8CA54-3FAD-4393-B9AD-39521AE7EB7EQ42861413-C402D4FA-9273-4E26-8640-9BE934160648Q43622668-34075531-2774-4083-AA17-82CAD032D413Q43944832-0FF34BEF-0F1E-46A8-A78A-51ECFF82D9AFQ44080548-0D03E895-C159-4C5D-BCB3-5BDDC325E5A1Q44847532-0434410F-42C7-4E11-9604-1338EF942EA5Q48204742-879A14BE-04B7-40C3-9EEE-60C0EF45597CQ51251554-9725F9E6-9824-4FAB-ADE5-F4A8CF4CBFDCQ53925847-32874AFF-1966-40B9-AF22-16A5ACEC23D2Q54594205-66A80BE1-323D-48DB-932A-5BA3D802F7FA
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Rabeprazole.
@en
type
label
Rabeprazole.
@en
prefLabel
Rabeprazole.
@en
P1433
P1476
Rabeprazole.
@en
P2093
P304
261-7; discussion 268
P356
10.2165/00003495-199855020-00009
P577
1998-02-01T00:00:00Z
P6179
1033214028